Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Webcast

Adicet Bio to Present Preclinical Data from Allogeneic Gamma Delta T Cell Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting


Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first in class, allogeneic chimeric antigen receptor (CAR) and adaptor (CAd) gamma delta T cell therapies today announced four preclinical abstract poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting taking place November 8-12, 2022 in Boston, MA.

Poster Presentations:

Abstract Title: Innate-Enhanced Chimeric Adaptors (CAd): A Newly-Described Approach for Augmenting Potency of ?? T Cell Immunotherapy
Poster/Abstract Number: 198
Presenting Author: Marissa Herrman, Ph.D.
Date/Time: November 11, 2022 from 9:00am ? 9:00pm EST

Title: Preclinical Discovery and Characterization of Allogeneic anti-PSMA ?? CAR T Therapy for Prostate Cancer
Poster/Abstract Number: 203
Presenting Author: Nitya S. Ramadoss, Ph.D.
Date/Time: November 10, 2022 from 9:00am ? 9:00pm EST

Abstract Title: Allogeneic "off-the-shelf" ?? T cells modified with CD27- containing CAR for targeting CD70+ cancers
Poster/Abstract Number: 246
Presenting Author: Kevin P. Nishimoto, Ph.D.
Date/Time: November 11, 2022 from 9:00am ? 9:00pm EST

Abstract Title: Preclinical Discovery and Evaluation of Allogeneic "off-the-shelf" ?? CAR T Cells Targeting B7-H6+ Tumors
Poster/Abstract Number: 247
Presenting Author: Kevin P. Nishimoto, Ph.D.
Date/Time: November 10, 2022 from 9:00am ? 9:00pm EST

The abstracts will be available in a Journal for ImmunoTherapy of Cancer (JITC) supplement, which will be published on Monday, November 7 at 8:00am EST on www.sitcancer.org.

R&D Webcast

Adicet will host an R&D webcast presentation on Thursday, November 10, 2022 at 9:00am EST to provide an overview of its R&D pipeline.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic chimeric antigen receptor (CAR) and adaptor (CAd) gamma delta T cell therapies engineered to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at http://www.adicetbio.com.


These press releases may also interest you

at 00:29
Cadence Education, LLC. ("Cadence Education"), one of the largest providers of early childhood education in North America, announced that its 2022 annual company-wide fundraising St. Jude Trike-A-Thon event has raised $330,145. This brings Cadence...

at 00:00
This webinar will enable attendees to understand and comply with the FDA's cell and gene therapy...

30 nov 2022
IVERIC bio, Inc. (the "Company"), today announced the pricing of an upsized underwritten public offering of 13,350,000 shares of its common stock at a price to the public of $22.50 per share, less underwriting discounts and commissions. In addition,...

30 nov 2022
CNS Pharmaceuticals, Inc. ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the pricing of a public...

30 nov 2022
Aura Biosciences, Inc. ("Aura") , a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the pricing of an underwritten public offering of...

30 nov 2022
Liminatus Pharma LLC ("Liminatus"), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies and Iris Acquisition Corp ("Iris") , a publicly traded special purpose acquisition company ("SPAC") formed for the...



News published on 5 october 2022 at 08:10 and distributed by: